DR. REDDY'S LABORATORIES LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6,406 INR | +2.66% |
|
+6.61% | +10.48% |
| 06-28 | Dr. Reddy's to Co-market Zydus' Breast Cancer Treatment in India | MT |
| 06-28 | India plans incentives for diabetes, obesity drug makers in 2026, government official says | RE |
ETFs positioned on Dr. Reddy's Laboratories Limited
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.01% | 15 M€ | -3.82% | ||
| 0.01% | 8 M€ | +0.16% | - | |
| 0.00% | 7 M€ | +0.11% | - |
Dr. Reddy's Laboratories specializes in developing, producing, and selling pharmaceutical products. Net sales break down by activity as follows:
- sales of generic medications (79.9%): brand-name or generic prescription medications and OTC medicines;
- sales of active ingredients (15.7%). The group also supplies customized pharmaceutical services;
- other (4.4%): sales of generic biopharmaceutical products, development of molecular agents, etc.
Net sales are distributed geographically as follows: India (18.8%), the United States (45%), Russia (9.9%) and other (26.3%).
Sector
Pharmaceuticals
Calendar
2024-07-15
- Détachement de for final dividend
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
HOLD
Number of Analysts
36
Last Close Price
6,406
INR
Average target price
6,161
INR
Spread / Average Target
-3.81%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +10.48% | 12.45B | |
| +55.32% | 819B | |
| -6.75% | 351B | |
| +13.56% | 329B | |
| +10.68% | 298B | |
| +16.57% | 242B | |
| +2.04% | 225B | |
| +13.31% | 217B | |
| +8.48% | 168B | |
| -2.81% | 158B |
- Stock Market
- Equities
- DRREDDY Stock
- Funds and ETFs Dr. Reddy's Laboratories Limited
